<SEC-DOCUMENT>0001140361-22-029023.txt : 20220810
<SEC-HEADER>0001140361-22-029023.hdr.sgml : 20220810
<ACCEPTANCE-DATETIME>20220810131618
ACCESSION NUMBER:		0001140361-22-029023
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220810
DATE AS OF CHANGE:		20220810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		221151204

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>brhc10040661_defa14a.htm
<DESCRIPTION>DEFA 14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="font-size: 14pt;">
        <div style="text-align: center; font-weight: bold;">UNITED STATES</div>
      </div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div>
        <div style="text-align: center; font-weight: bold;"> <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;"><font style="font-size: 12pt;"> </font><br>
        </div>
        <div style="text-align: center; font-weight: bold; font-size: 18pt;">SCHEDULE 14a</div>
      </div>
      <div style="text-align: center; font-weight: bold;">(RULE 14a-101)</div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;">SCHEDULE 14A INFORMATION</div>
      </div>
      <div>
        <div style="text-align: center;"> <br>
        </div>
        <div style="text-align: center;">Proxy Statement Pursuant to Section 14(a) of</div>
        <div style="text-align: center;">the Securities Exchange Act of 1934</div>
        <div style="text-align: center;"> <br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb7083e52c4a64480a33e5c36bea12232" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: bottom;" colspan="2">
              <div style="color: rgb(0, 0, 0);">Filed by the Registrant &#9746;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;" colspan="2">
              <div>
                <div style="color: rgb(0, 0, 0);">Filed by a Party other than the Registrant &#9744;</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;" colspan="2">
              <div style="color: rgb(0, 0, 0);">Check the appropriate box:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.83%; vertical-align: bottom;">&#160;&#9744;</td>
            <td style="width: 96.17%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Preliminary proxy statement</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.83%; vertical-align: bottom;">&#160;&#9744;</td>
            <td style="width: 96.17%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.83%; vertical-align: bottom;">&#160;&#9744;</td>
            <td style="width: 96.17%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Definitive Proxy Statement</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.83%; vertical-align: bottom;">&#160;&#9746;</td>
            <td style="width: 96.17%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Definitive Additional Materials</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.83%; vertical-align: bottom;">&#160;&#9744;</td>
            <td style="width: 96.17%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Soliciting Material Pursuant to &#167;240.14a-12</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">CATALYST BIOSCIENCES, INC.</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; color: rgb(0, 0, 0);">(Name of Registrant as Specified in its Charter)</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; color: rgb(0, 0, 0);">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</div>
      <div><br>
      </div>
      <div style="text-indent: 18pt; color: rgb(0, 0, 0);">Payment of Filing Fee (Check the appropriate box):</div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zf5fd11279902402caadf4600eccc49ed" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 45pt; vertical-align: top;">
                <div style="margin-left: 18pt; color: rgb(0, 0, 0);">&#9746;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">No fee required.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zaba0d202932845beb6e1e389ac72f146" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 45pt; vertical-align: top;">
                <div style="margin-left: 18pt; color: rgb(0, 0, 0);">&#9744;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Fee paid previously with preliminary materials.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z6b7d36676a034d3e9deb19e5b18c42bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 45pt; vertical-align: top;">
                <div style="margin-left: 18pt; color: rgb(0, 0, 0);">&#9744;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div>
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>On August 10, 2022, Catalyst Biosciences, Inc. issued the following press release:</div>
      <div> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board</div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic;">Encourages Stockholders to Vote on the WHITE Proxy Card</div>
      <div><br>
      </div>
      <div>SOUTH SAN FRANCISCO, Calif., August 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the &#8220;Company,&#8221; &#8220;Catalyst&#8221; or &#8220;we&#8221;) announced that it
        has received a notice from JDS1, LLC (&#8220;JDS1&#8221;) that JDS1 has withdrawn the nominations of Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (the &#8220;Withdrawn Candidates&#8221;) for election to the Catalyst Board of Directors at the Catalyst 2022 annual
        meeting of stockholders (the &#8220;2022 Annual Meeting&#8221;), which is scheduled for August 15, 2022.</div>
      <div><br>
      </div>
      <div>Accordingly, any votes cast for the Withdrawn Candidates will be disregarded at the 2022 Annual Meeting. JDS1 has not indicated whether it intends to submit
        votes cast by Catalyst stockholders on JDS1&#8217;s gold proxy card with respect to the other matters on the agenda at the 2022 Annual Meeting.</div>
      <div><br>
      </div>
      <div>Catalyst encourages shareholders wishing to have their votes counted at the meeting to vote using the Company&#8217;s <font style="font-weight: bold;"><u>WHITE</u></font> proxy card.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">About Catalyst Biosciences</div>
      <div>Catalyst is a biotechnology company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems.
        After the transaction of its complement pipeline, Catalyst&#8217;s product candidates consist of the coagulation related assets marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), dalcinonacog alfa (&#8220;DalcA&#8221;), and CB 2679d-GT. MarzAA is a SQ administered next
        generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy
        construct harboring the DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials and are available for partnering. CB 2679d-GT has obtained preclinical proof-of-concept and is also available for
        partnering.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Additional Information and Where to Find It</div>
      <div>Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) has filed a definitive proxy statement, an accompanying WHITE proxy card and other relevant documents with the
        Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the solicitation of proxies for the Company&#8217;s 2022 annual meeting of stockholders (the &#8220;Annual Meeting&#8221;). BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO
        READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY&#8217;S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able
        to obtain a copy of the definitive proxy statement and other documents filed by the Company with the SEC free of charge from the SEC&#8217;s website at www.sec.gov. In addition, copies will be available at no charge by selecting &#8220;Financials &amp;
        Filings&#8221; in the &#8220;Investors&#8221; tab of the Company&#8217;s website at www.catalystbiosciences.com.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Certain Information Regarding Participants in the Solicitation</div>
      <div>The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from the Company&#8217;s stockholders in
        connection with the Annual Meeting. The names of these directors and executive officers and their respective direct and indirect interests, by security holdings or otherwise, in the Company are set forth in the Company&#8217;s definitive proxy statement
        filed with the SEC on July 19, 2022.</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-weight: bold;">Forward-Looking Statements</div>
      <div>This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without limitation,
        potential uses of and markets for MarzAA, DalcAA and CB 2679-GT, and Catalyst&#8217;s plans to continue to explore strategic alternatives. Actual results or events could differ materially from the plans, intentions, expectations, and projections
        disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risks that Catalyst&#8217;s obligations and liabilities will be greater than currently
        anticipated, that the pending litigation with JDS1 will not be resolved in a timely manner and the expenses associated with that litigation will be greater than anticipated, that Catalyst will not be able to identify strategic partners interested
        in MarzAA, DalcAA, CB 2679-GT or any other transaction with the Company, and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 31,
        2022, the Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Contact Information</div>
      <div>Trisha Colton</div>
      <div>Catalyst Biosciences, Inc.</div>
      <div>investors@catbio.com</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
